Meta-analysis reveals no significant benefit of immunotherapy-docetaxel combinations on overall survival in mCRPC, suggesting further trials are needed.
Key Points
MAIN FINDING: Immunotherapy and docetaxel combinations show no significant advantage over docetaxel alone in metastatic castration-resistant prostate cancer.
KEY EVIDENCE: Overall survival rates (HR = 0.95, P = 0.56) and progression-free survival (HR = 0.93, P = 0.32) did not differ significantly between groups.
APPROACH: Four randomised controlled trials involving 2,289 participants were analyzed using fixed or random-effects models based on data heterogeneity.
SIGNIFICANCE: Findings indicate the need for caution and further rigorous trials to evaluate the effectiveness of these combinations in metastatic castration-resistant prostate cancer.